{
    "root": "4552ad10-d451-4a09-8640-bf7a5d9cc5d9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pioglitazone",
    "value": "20210701",
    "ingredients": [
        {
            "name": "PIOGLITAZONE HYDROCHLORIDE",
            "code": "JQT35NPK6C"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE CALCIUM",
            "code": "UTY7PDF93L"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        }
    ],
    "indications": "Monotherapy and Combination Therapy\n                  \n                  Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)].\n                  \n                     Important Limitations of Use\n                  \n                  Pioglitazone tablets exert their antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. \n                  Use caution in patients with liver disease [see Warnings and Precautions (5.3)].",
    "contraindications": "Initiate pioglitazone tablets at 15 mg or 30 mg once daily. Limit initial dose to 15 mg once daily in patients with NYHA Class I or II heart failure. ( 2.1 ) If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. ( 2.1 ) Obtain liver tests before starting pioglitazone tablets. If abnormal, use caution when treating with pioglitazone tablets, investigate the probable cause, treat (if possible) and follow appropriately. Monitoring liver tests while on pioglitazone tablets is not recommended in patients without liver disease. ( 5.3 )",
    "warningsAndPrecautions": "Pioglitazone Tablets, USP are available as follows:\n                  15 mg: white to off-white, round convex tablets, debossed with “TEVA” on one side of the tablet and “7271” on the other side, available in bottles of 30 (NDC 0093-7271-56), 90 (NDC 0093-7271-98), and 500 (NDC 0093-7271-05).\n                  30 mg: white to off-white, round flat tablets, debossed with “TEVA” on one side of the tablet and “7272” on the other side, available in bottles of 30 (NDC 0093-7272-56), 90 (NDC 0093-7272-98), and 500 (NDC 0093-7272-05).\n                  45 mg: white to off-white, round flat tablets, debossed with “TEVA” on one side of the tablet and “7273” on the other side, available in bottles of 30 (NDC 0093-7273-56), 90 (NDC 0093-7273-98), and 500 (NDC 0093-7273-05).",
    "adverseReactions": "Initiation in patients with established NYHA Class III or IV heart failure [see \n                        Boxed Warning]. \n                     Use in patients with known hypersensitivity to pioglitazone or any other component of pioglitazone tablets."
}